MHRA Special Authorisation (Specials)

The MHRA (Medicines and Healthcare products Regulatory Agency) Specials scheme is a UK regulatory pathway under which a licensed Specials manufacturer or importer may prepare or procure an unlicensed medicinal product to fulfil a prescription for a named patient, where no suitably licensed product is available. The scheme operates under Regulation 167 of the Human Medicines Regulations 2012 and provides a lawful route for patients to access medicines that do not hold a UK marketing authorisation.

Why it matters in peptide research

Several peptide and biological products that are either fully licensed in European or post-Soviet markets or are in active clinical development exist in a regulatory gap in the UK: they are not licensed medicines, yet there is legitimate clinical interest in prescribing them. Cerebrolysin is a prominent example — it holds regulatory approval in multiple European and Asian countries as a neuroprotective treatment for stroke and dementia, but does not hold a UK marketing authorisation. Under the Specials pathway, a UK prescriber (typically a specialist physician) can write a named-patient prescription, and a Specials-licensed pharmacy can legally import and supply the product.

This pathway is significant because it is one of the few lawful UK routes for patient access to certain peptide-adjacent products without requiring the patient to import medicines personally — a higher-risk and legally ambiguous activity. The Specials framework places several obligations on the supply chain: the importing pharmacy must hold an MHRA Specials licence (MS licence or Manufacturing Licence with Specials authorisation), must satisfy themselves that no suitable licensed alternative exists, must maintain traceability records, and must ensure the product meets quality standards appropriate to an unlicensed medicine.

Researchers and clinicians should note that Specials authorisation is strictly a named-patient, prescriber-initiated pathway — it does not constitute a general licence to stock or sell unlicensed medicines to any customer, and Specials cannot be advertised or promoted to the public.

Peptides / stacks that act on this

• Cerebrolysin — porcine brain-derived neuropeptide mixture licensed in Europe but unlicensed in the UK; accessed via the MHRA Specials pathway on a named-patient basis

Common misconceptions

The MHRA Specials scheme is sometimes confused with the MHRA Exemptions for research or the Clinical Trial Authorisation (CTA) pathway. These are different instruments: Specials are for individual patient supply under a clinical prescription; CTAs are required for systematic study of an unlicensed product in human subjects. Ordering a Specials product for a research study rather than a named patient would not be compliant with the scheme's intent.